Floatz logo

Solu-Cortef

Lymphoblastic Lymphoma

St. Jude Children's Research HospitalPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
73/ 100

Competitive context

73 Active assets in the Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 4BBB
Cladribine
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 2BBB
MERCAPTOPURINE ANHYDROUS
City of Hope Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant
A
Indicative ·
81 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →